Statera Biopharma - Delisted Pink Sheet
Statera Biopharma is currently unavailable and cannot be used in your analysis. The information on this page reflects the last day Statera Biopharma was actively traded.
Valuation
Check how we calculate scores
Statera Biopharma Risk Profiles
Risk Adjusted Performance | (0.09) | |||
Jensen Alpha | (1.60) | |||
Total Risk Alpha | (3.15) | |||
Treynor Ratio | 3.27 |
View Statera Biopharma Related Equities
Risk & Return | Correlation |
Statera Biopharma Corporate Management
George Wagner | Ex Affairs | Profile | |
Dr Buckheit | Chief Officer | Profile | |
Christopher Zosh | Interim Fin | Profile | |
Todd Headley | Exec Devel | Profile | |
Michael Handley | Pres CEO | Profile |
Still Interested in Statera Biopharma?
Investing in delisted pink sheets can be risky, as the pink sheet is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Statera Pink Sheet
If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |